Exploring the sensory profile and pharmacogenetic biomarkers in child and youth ADHD patients undergoing methylphenidate (MPH) treatment: a systematic review conducted in European studies
Methylphenidate (MPH) is the first-line treatment for Attention-Deficit/Hyperactivity Disorder (ADHD), a condition that disrupts daily functioning. Research indicates that individuals with ADHD often experience sensory processing impairments, regardless of co-occurring conditions. Given the growing...
| Autores: | , , , , , , , , , |
|---|---|
| Tipo de recurso: | artículo |
| Fecha de publicación: | 2025 |
| País: | España |
| Institución: | Universidad de Santiago de Compostela (USC) |
| Repositorio: | Minerva. Repositorio Institucional de la Universidad de Santiago de Compostela |
| Idioma: | inglés |
| OAI Identifier: | oai:minerva.usc.gal:10347/43741 |
| Acceso en línea: | https://hdl.handle.net/10347/43741 |
| Access Level: | acceso abierto |
| Palabra clave: | ADHD Methylphenidate Stimulants Sensory profile Sensory processing Pharmacogenetics |
| Sumario: | Methylphenidate (MPH) is the first-line treatment for Attention-Deficit/Hyperactivity Disorder (ADHD), a condition that disrupts daily functioning. Research indicates that individuals with ADHD often experience sensory processing impairments, regardless of co-occurring conditions. Given the growing interest in pharmacogenetics to personalise treatments and minimise side effects, this study aims to characterise the sensory profiles of in child and youth ADHD patients treated with MPH and investigate potential pharmacogenetic biomarkers that could be associated with treatment outcomes or sensory-related side effects. Following PRISMA guidelines, a systematic review focused on sensory profiles in ADHD patients receiving MPH and the pharmacogenetic biomarkers that might explain their sensory processing while on MPH treatment was conducted using four major databases (PubMed, Web of Science, PsycINFO, and Scopus) to include studies from the past 25 years. After screening 568 articles, seven studies met the inclusion criteria. None of them aimed to study pharmacogenetic biomarkers related to sensory outcomes. Findings showed that ADHD children treated with MPH had improved pain perception and postural balance but worse odour discrimination compared to unmedicated patients. Other sensory factors, such as noise sensitivity and odour identification, did not yield statistically significant results. Further research is needed to understand the mechanisms behind sensory processing differences, as well as the impact of factors such as sex and co-medication. Furthermore, the gap in understanding pharmacogenetic biomarkers for sensory responses suggests new research questions, which could ultimately improve diagnostic and therapeutic strategies for ADHD and sensory-related disorders. |
|---|